202 related articles for article (PubMed ID: 16113602)
21. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
22. [Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells].
Yin XR; Zhang M; Luo YY; Lin X; He PC; Chen LM; Cai RB; Guo GL
Ai Zheng; 2005 Jun; 24(6):657-62. PubMed ID: 15946473
[TBL] [Abstract][Full Text] [Related]
23. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
24. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
25. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.
Franki SN; Steward KK; Betting DJ; Kafi K; Yamada RE; Timmerman JM
Blood; 2008 Feb; 111(3):1504-11. PubMed ID: 17993615
[TBL] [Abstract][Full Text] [Related]
27. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
Neeson P; Pan ZK; Paterson Y
Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
[TBL] [Abstract][Full Text] [Related]
28. Rejection of tumors of the B cell lineage by idiotype-vaccinated mice.
Haimovich J; Kukulansky T; Weissman B; Hollander N
Cancer Immunol Immunother; 1999 Feb; 47(6):330-6. PubMed ID: 10203063
[TBL] [Abstract][Full Text] [Related]
29. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.
Moshitzky S; Kukulansky T; Haimovich J; Hollander N
Immunol Cell Biol; 2008; 86(3):261-7. PubMed ID: 18195726
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma.
Cohen S; Haimovich J; Hollander N
J Immunol; 2009 Feb; 182(3):1667-73. PubMed ID: 19155516
[TBL] [Abstract][Full Text] [Related]
31. A mouse model for immunotherapy of myeloma.
Bogen B
Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
[TBL] [Abstract][Full Text] [Related]
32. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
[TBL] [Abstract][Full Text] [Related]
33. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
Dhodapkar KM; Krasovsky J; Williamson B; Dhodapkar MV
J Exp Med; 2002 Jan; 195(1):125-33. PubMed ID: 11781371
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.
Hájek R; Butch AW
Med Oncol; 2000 Feb; 17(1):2-15. PubMed ID: 10713654
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H
Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cell-based immunotherapy in multiple myeloma.
Yi Q
Leuk Lymphoma; 2003 Dec; 44(12):2031-8. PubMed ID: 14959845
[TBL] [Abstract][Full Text] [Related]
37. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine.
Adam C; Mysliwietz J; Mocikat R
J Transl Med; 2007 Mar; 5():16. PubMed ID: 17359532
[TBL] [Abstract][Full Text] [Related]
38. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
Wen YJ; Barlogie B; Yi Q
Blood; 2001 Mar; 97(6):1750-5. PubMed ID: 11238117
[TBL] [Abstract][Full Text] [Related]
39. Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype.
Ghosh SK; White LM; Ghosh R; Bankert RB
J Immunol; 1990 Jul; 145(1):365-70. PubMed ID: 1972719
[TBL] [Abstract][Full Text] [Related]
40. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.
Cesco-Gaspere M; Benvenuti F; Burrone OR
Cancer Immunol Immunother; 2005 Apr; 54(4):351-8. PubMed ID: 15692846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
